At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
LY2881835 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating LY2881835 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This will be the first study in which LY2881835 is given to humans in order to evaluate the safety and any side effects of LY2881835 in humans as well as how long LY2881835 stays in the body and its effect on blood sugar levels. The study consists of two parts. In part A, healthy subjects will participate and in part B, patients with type 2 Diabetes Mellitus (T2DM) will participate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartMay 2011
Primary CompletionAug 2011
TodayJul 2026
First PostedMay 24, 2011
Enrollment StartMay 24, 2011
Primary CompletionAug 17, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.1 years ago
Interventions
LY2881835drug
Administered orally
Placebodrug
Administered orally